English
Abbott Header Logo
Logo Image

The Heart of 
the Matter

Request Information
Heart failure management video
Tennis banner image
Tennis banner image
Tennis banner image

Optimized diagnosis to tackle the global burden of heart failure

Heart failure may have a complex presentation and can be difficult to diagnose due to non-specific symptoms, such as dyspnea.1,2 This can result in poor prognosis or misdiagnosis which can lead to significant clinical, social and economic burdens.3,4
The accurate assessment of patients is vital for optimizing resources and improving outcomes.

64.7 million adults in the US are living with HF5

>1 million HF hospitalizations annually in the US6

1 in 5 HF patients are re-hospitalized within 30 days7

 

Economic burden of HF is estimated at >$30 billion each year5

blue background image
blue background image

Measuring natriuretic peptide (NP) levels has shown benefit in almost every aspect of Heart Failure care

Abbott’s high-performance test is designed not to interfere with biotin, enabling the accurate detection of NT-proBNP concentrations.
The results, when used in conjunction with other clinical information, help define clinical pathways that facilitate accurate diagnoses and optimize patient care.8, 9

Improve lab operational efficiency with accurate and reliable results

The Alere NT-proBNP assay rounds out Abbott’s cardiac portfolio aiding physicians to confidently rule out patients with non-cardiac dyspnea and aid in the diagnosis and management of HF.

Operational efficiencies include:

Consolidation of hsTnI and NT-proBNP testing to one lithium heparin tube on the Alinity i platform8,10

Reduction in consumable waste with expiration stable reagents and calibrators8-11

Extended instrument run time due to minimal calibrations required8

Optimized staff workflow with less analyzer hands-on time12

ALL IN ONE.
The Alinity ci system consolidates cardiac biomarker testing of
1 patient to 1 tube on 1 platform.8,10




Hear another perspective on Heart Failure Management

Learn more about HF management and natriuretic peptides by watching this presentation with Dr. Jim Januzzi, physician at Massachusetts General Hospital and Director of Heart Failure and Biomarker Trials at Baim Institute for Clinical Research.

Heart Failure Management video thumbnail

Find out more

Review the Alere NT-proBNP assay brochure to learn how the addition of this test can optimize the care you provide to HF patients.

Download the brochure
Request information
background image
background image
Intended Use

 

The Alere NT-proBNP for Alinity i assay is a chemiluminescent microparticle immunoassay (CMIA) used for the in vitro quantitative determination of N-terminal pro B-type natriuretic peptide (NT-proBNP) in human serum and plasma on the Alinity i system.

In the emergency department, measurements of NT-proBNP are used as an aid in the diagnosis of heart failure (HF) in patients with clinical suspicion of new onset or worsening HF.

IMPORTANT SAFETY INFORMATION

Instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from these instructions.

For laboratory professional use only.

  • Rx Only: For use by or on the order of a physician only.
  • This product requires the handling of human specimens. It is recommended that all human-sourced materials and all consumables contaminated with potentially infectious materials be considered potentially infectious and handled in accordance with the OSHA Standard on Bloodborne Pathogens.
  • This product contains sodium azide. Contact with acids liberates very toxic gas. Dispose of contents/containers in accordance with local regulations.
Back To Top

Explore

Immunoassays

Abbott's high-quality immunoassay menu helps laboratories meet requirements to be reliable, accurate and precise.

Explore Immunoassays

Mild Traumatic Brain Injury

Learn how Abbott has helped physicians evaluate suspected mild traumatic brain injury (mTBI).

Learn about mtbi

Alinity Family

Discover how Alinity uses powerful technology to help redefine and improve operational productivity and confidence in your laboratory.

Get to know Alinity
References
  1. Lin DC, Diamandis EP, Januzzi JL, et al. Natriuretic peptides in heart failure. Clin Chem. 2014;60(8):1040-1046.
  2. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.
  3. Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 118(17):3272-3287.
  4. Lippi G, Giuseppe L, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Medical Journal. 2020:15.
  5. Centers for Disease Control and Prevention. About Heart Failure | Heart Disease. Accessed March 12, 2025. https://www.cdc.gov/heart-disease/about/heart-failure.html
  6. Lahoz R, Fagan A, McSharry M, et al. Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink. ESC Heart Fail. 2020(4):1688-1699.
  7. Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356.
  8. Alere NT-proBNP for Alinity I IFU. 819132R01. January 2025.
  9. Pandit K, Mukhopadhyay P, Ghosh S, et al. Natriuretic peptides: Diagnostic and therapeutic use. Indian J Endocrinol Metab. 2011;15(4):345–53.
  10. Alinity I STAT High Sensitivity Troponin-I IFU H14937R02. May 2023.
  11. Alere NT-proBNP Cal IFU. H21307R05. January 2025.
  12. Alinity ci-series Operations Manual. 80000071-108. April 2021.

 

 

Logo Image

©2025 Abbott. All rights reserved.

All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos may be a model. Please read the Legal Notice for further details.

All ARCHITECT analyzers, Alinity hq, CELL-DYN Ruby and CELL-DYN Emerald 22 AL instruments are Class I laser products. ACCELERATOR APS and ACCELERATOR a3600 are Class II laser products.

The Alinity, ARCHITECT and CELL-DYN systems are intended for performing in vitro diagnostic assays on samples of human origin. Read the instructions in the system manuals and labeling and/or reagent instructions carefully.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

NO